Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Genflow Biosciences Plc LSE:GENF London Ordinary Share GB00BP2C3V08 ORD GBP0.0003
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 2.15 2.10 2.20 2.15 2.15 2.15 146,863 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 6

Genflow Biosciences PLC Half-year results

30/09/2022 7:02am

UK Regulatory (RNS & others)


Genflow Biosciences (LSE:GENF)
Historical Stock Chart


From Aug 2022 to Feb 2023

Click Here for more Genflow Biosciences Charts.

TIDMGENF

RNS Number : 3100B

Genflow Biosciences PLC

30 September 2022

PRESS RELEASE

30 September 2022

Genflow Biosciences Plc

("Genflow" or "the Company")

HALF YEAR RESULTS

Genflow (LSE: GENF) is pleased to announce its half year results for the six-month period ended 30 June 2022.

Chairman's Statement

It is with pleasure that I take this opportunity to update shareholders of Genflow Biosciences Plc ("Genflow" or "the Company") on the Company's performance during the first six months of 2022.

Following the Company's successful listing to the Standard Segment of the London Stock Exchange in January 2022 ("Admission"), making it the first longevity focussed company listed in Europe, it quickly (March 2022) secured a non-dilutive research grant award of up to EUR3.375m from the regional government of Wallonia in southern Belgium SPW ("Grant"). The Grant will cover two years of costs of the pre-clinical research and development program 'AAV/SIRT6 Gene Therapy for the Treatment of Progeria' conducted by our subsidiary, Genflow Biosciences Srl ("Genflow BE"), within the European Community. The total financed program is for up to EUR3,375,770 covering 70% of the Group's EU research and development. These funds are in addition to the placing monies the Company received from its oversubscribed placing at Admission.

During the period, the Company was pleased to announce it had entered into collaborative research agreements with some of the most prestigious organisations in the biotechnology space.

In March 2022, the Company commenced a scientific research collaboration with the University of Rochester's Aging Research Center (RoAR), one of the world's pre-eminent age research facilities. The collaborative research will be spearheaded by a member of the Company's scientific advisory board, Dr Vera Gorbunova, who is an internationally acclaimed leading scientist in the areas of DNA repair and the aging process. The data obtained from the collaboration will support the pre-clinical trials Genflow is undertaking and will expedite its development of gene therapies.

Further to this, in May 2022, the Company entered into a collaborative research agreement with Organips, a France-based biotechnology company founded by Prof Jean Marc Lemaitre. The research programme entitled "Evaluation of SIRT6 Activity On iPSC Derived WRN Liver Organoids As A Prerequisite For SIRT6 Therapy", will seek to demonstrate both the safety, and efficacy, of SIRT6 in reliable Werner syndrome models. Organips has significant expertise in taking old cells and rejuvenating them, and Prof Jean Marc Lemaitre (who has published several papers on reprogramming cells), is a leader in this field and has filed several patents.

The most recent partnership (entered into in late June 2022) is with Magnitude Biosciences Limited ("Magnitude"), a UK-based, specialist biotechnology research organisation that supports drug discovery and product development. Magnitude leverages Artificial Intelligence and uses nematode worms, called C. elegans, for in-vivo testing in aging research, to accelerate early, pre-clinical drug development for biotech and pharmaceutical firms. Its sophisticated 'Magnitude Biosciences Healthspan technology' enables it to monitor large numbers of C. elegans under multiple conditions and effectively assess the impact of compounds on health and longevity.

Through the collaboration with Magnitude, Genflow's future therapeutic developments will be accelerated by Magnitude's innovative technology which has the capacity to significantly expedite product development, supported by sophisticated machine monitoring.

Changes to the Board of Directors

In June 2022, the Company welcomed two new Independent Non-Executive Directors, Tamara Joseph and Dr Guy-Charles Fanneau de la Horie, to its Board of Directors.

Tamara has extensive experience in both early-stage and commercial biotech companies in the US. Her outstanding track record in biotechnology, with particular exposure to listed firms in the US, dovetails with Genflow's growing exposure in the US following its recent distinguished collaborations summarised above.

Dr Guy-Charles has built, and led, biotech executive teams over the past 20 years where he has acted as Chief Executive Officer and successfully led IPOs and completed multiple fundraisings. His expertise in the biotechnology field and in capital markets specifically, will be an invaluable asset for Genflow as the Company continues to grow and perform against its stated strategy.

In June 2022, the Company also announced the resignation of Dr Gabrielle Silver who stepped down from the Board to focus on her other board roles, and Professor Andrew Scott who stepped down in order to devote more time to his research and writing, aimed at raising awareness around longevity.

Financial Overview

As at 30 June 2022, the Group had cash reserves of GBP2,945,624, up from GBP224,004 as at 1 January 2022 and the Company remains debt free.

On 17 January 2022, the Company successfully listed on the Standard Segment of the London Stock Exchange. The fundraise at the time of Admission consisted of issuing 47,036,500 Ordinary Shares at 8p, receiving placing proceeds of GBP3,499,516 net of commissions.

Administration expenses for 30 June 2022 totalled GBP696,402 (30 June 2021: GBP372,291), which primarily consisted of legal and professional fees totalling GBP267,535 for the period (30 June 2021: GBP135,431), which are largely associated with Admission. The Group also has costs of GBP97,304 (30 June 2021: GBP75,551) in respect of research and development activities.

Other Comprehensive Income was charged with a translation gain of GBP14,017 upon converting the Subsidiary's results for the period since acquisition to GBP.

Future

On behalf of the Board, I thank you for your continued support and look forward to continuing to build on Genflow's position in the longevity sector both in Europe and the US. The strategic collaborations combined with the deep expertise of Genflow's management team and the Company's strong cash position, enables us to look to the future with confidence.

Yassine Bendiabdallah

Chairman

Consolidated Statement of Financial Position

As at 30 June 2022

 
 
                                         Unaudited         Unaudited         Audited 
                                           30 June           30 June     31 December 
                                Note          2022              2021            2021 
 
 
 Current assets 
 Trade and other receivables                70,527            33,473          52,547 
 Cash and cash equivalents               2,945,624           535,919         224,004 
                                      ------------      ------------  -------------- 
 Total Current assets                    3,016,151           569,392         276,551 
                                      ------------      ------------  -------------- 
 Total assets                            3,016,151           569,392         276,551 
                                      ------------      ------------  -------------- 
 
 Current liabilities 
 Trade and other payables                  149,288           133,990         221,427 
                                      ------------      ------------  -------------- 
 Total Current liabilities                 149,288           133,990         221,427 
                                      ------------      ------------  -------------- 
 
 Total liabilities                         149,288           133,990         221,427 
                                      ============      ============  ============== 
 Net Assets                              2,866,863           435,402          55,124 
                                      ============      ============  ============== 
 
 Equity 
 Share capital                  6           87,752            22,886          73,371 
 Share premium                           4,190,900           659,807         633,765 
 Other reserves                            170,200           126,771         156,183 
 Retained earnings/loss                (1,581,989)         (374,062)       (808,195) 
                                      ============      ============  ============== 
 Total equity                            2,866,863           435,402          55,124 
                                      ============      ============  ============== 
 
 

The financial statements were approved and authorised for issue by the Board of Directors on 29 September 2022 and were signed on its behalf by:

Eric Leire

Chief Executive Officer

Consolidated Statement of Comprehensive Income

For The Six Months Ended 30 June 2022

 
 
                                                      Notes   Unaudited  Unaudited 
                                                               6 Months   6 Months       Audited 
                                                                  ended      ended    Year ended 
                                                                30 June    30 June   31 December 
                                                                   2022       2021          2021 
 Administrative expenses                                4     (696,402)  (372,291)     (938,096) 
 Other losses                                                  (77,082)    (1,771)      (50,000) 
                                                                                    ------------ 
 Operating loss                                               (773,484)  (374,062)     (988,096) 
 
 Finance income/(costs)                                           (310)          -          (99) 
 Gain on revaluation of assets 
  held at fair value through profit 
  and loss                                                            -          -             - 
 Foreign exchange                                                     -          -             - 
 
 Profit/(Loss) before tax                                     (773,794)          -     (988,195) 
 
 Tax expense                                                          -          -             - 
                                                              ---------  ---------  ------------ 
 
   Loss for the year from continuing 
   operations                                                 (773,794)  (374,062)     (988,195) 
                                                              ---------  ---------  ------------ 
 
   Profit from discontinued operations 
   - assets sold                                                      -          -             - 
 Loss from discontinued operations 
  - assets held for sale                                              -          -             - 
 
 Profit/ (Loss) for the period 
  / year attributable to owners 
  of the parent                                               (773,794)  (374,062)     (988,195) 
                                                              =========  =========  ============ 
 
 Other Comprehensive (loss) / 
  income: 
 Items that could be reclassified 
  to profit or loss 
 Exchange differences on translation 
  of foreign operations                                          14,017   (43,477)      (14,065) 
 
 
 Total comprehensive (loss) / 
 income for the period / year attributable 
 to owners of the parent                                      (759,777)  (417,539)   (1,002,260) 
                                                              =========  =========  ============ 
 
 Loss per share (cents) from continuing 
  operations attributable to owners 
  of the Parent - Basic & Diluted                          5    (0.267)     (0.17)       (0.593) 
 
 
 

Consolidated Statement of Cash Flows

For The Six Months Ended 30 June 2022

 
                                                      Unaudited   Unaudited 
                                                       6 Months    6 Months        Audited 
                                                          ended       ended     Year ended 
                                                        30 June     30 June    31 December 
                                                           2022        2021           2021 
 Cash flows used in operating activities: 
 Loss after taxation                                  (773,794)   (374,062)      (988,195) 
 Adjustments for: 
 Share based payments                                         -           -         18,960 
 Impairment of receivables                                    -           -         50,000 
 Net finance income                                          90           -             99 
 Increase in trade and other receivables               (17,980)    (33,658)       (49,668) 
 Increase in trade and other payables                     (139)     154,558        221,427 
 Foreign exchange                                        14,017       3,247              - 
--------------------------------------------------   ----------  ----------  ------------- 
 Net cash outflow from operating 
  activities                                          (777,806)   (249,915)      (747,377) 
--------------------------------------------------   ----------  ----------  ------------- 
 
 
 Cash flow used in investing activities: 
 Cash acquired through business combinations                  -     198,502        198,502 
 Loans granted to subsidiaries                                -           -              - 
--------------------------------------------------   ----------  ----------  ------------- 
 Net cash used in investing activities                        -     198,502        198,502 
--------------------------------------------------   ----------  ----------  ------------- 
 
 Cash flow from financing activities: 
 Proceeds from issue of shares                        3,762,830     587,332        783,711 
 Cost of share issue                                  (263,404)           -              - 
--------------------------------------------------   ----------  ----------  ------------- 
 Net cash generated from financing 
  activities                                          3,499,426     587,332        783,711 
--------------------------------------------------   ----------  ----------  ------------- 
 
 Net (decrease)/increase in cash 
  and cash equivalents                                2,721,620     535,919        224,004 
 Cash and cash equivalents at beginning                 224,004           -              - 
  of period / year 
 Cash and cash equivalents at end 
  of period                                           2,945,624     535,919        224,004 
--------------------------------------------------   ----------  ----------  ------------- 
 
 
 

Non- Cash Investing and Financing Activities

Unaudited 6 months ended 30 June 2022 - 900,000 Ordinary shares were issued at nominal value as non-cash consideration to three Directors of the Company in lieu of fees.

Unaudited 6 months ended 30 June 2022 - 203,833,878 Ordinary shares were issued at nominal value as non-cash consideration for the acquisition of Genflow Biosciences Srl, as part of a share for share exchange arrangement.

Audited Year ended 31 December 2021 - 8,500,00 Ordinary Shares were issued at nominal value and 474,000 new Ordinary Shares at a price of 4 pence per share in lieu of fees totalling GBP18,960.

Consolidated Statement of Changes In Equity

For The Six Months Ended 30 June 2022

 
 
                                           Share         Shares                                 Retained 
                        Share capital    premium   to be issued    Other reserves          earnings/loss         Total 
                        -------------  ---------  -------------  ----------------  ---------------------  ------------ 
Unaudited- 30 June 
2022 
At 1 January 2022              73,371    633,765              -           156,183              (808,195)        55,124 
Loss of the period                  -          -              -                 -              (773,794)     (773,794) 
Exchange differences 
 on translation of 
 foreign operations                 -          -              -            14,017                      -        14,017 
                        -------------  ---------  -------------  ----------------  ---------------------  ------------ 
Total comprehensive 
 income for the period              -          -              -            14,017              (773,794)     (759,777) 
                        -------------  ---------  -------------  ----------------  ---------------------  ------------ 
Transactions with 
owners 
Issue of share capital         14,111  3,748,809              -                 -                      -     3,762,920 
Costs of issue                      -  (263,404)              -                 -                      -     (263,404) 
Share based payments              270     71,730              -                 -                      -        72,000 
                        -------------  ---------  -------------  ----------------  ---------------------  ------------ 
Total Transactions 
 with owners                   14,381  3,557,135              -                 -                      -     3,571,516 
                        -------------  ---------  -------------  ----------------  ---------------------  ------------ 
At 30 June 2022 
 (unaudited)                   87,752  4,190,900              -      170,200                 (1,581,989)     2,866,863 
                        =============  =========  =============  ================  =====================  ============ 
 
 
Unaudited- 30 June 
2021 
At 18 January 2021                  -          -              -                 -                      -             - 
Loss of the period                  -          -              -                 -              (374,062)     (374,062) 
Other comprehensive 
 income for the period              -          -              -          (43,477)                      -      (43,477) 
                        -------------  ---------  -------------  ----------------  ---------------------  ------------ 
Total comprehensive 
 profit/(loss) for the 
 period                             -          -              -          (43,477)              (374,062)     (417,539) 
                        -------------  ---------  -------------  ----------------  ---------------------  ------------ 
Transactions with 
Owners 
Issue of ordinary 
 shares                        22,886    659,807              -                 -                      -       682,693 
Acquisition of 
 subsidiaries under 
 common control                     -          -              -           170,248                      -       170,248 
                        -------------  ---------  -------------  ----------------  ---------------------  ------------ 
Total Transactions 
 with owners                   22,886    659,807              -           170,248                      -       852,941 
                        -------------  ---------  -------------  ----------------  ---------------------  ------------ 
At 30 June 2021 
 (unaudited)                   22,886    659,807              -           126,771              (374,062)       435,402 
                        =============  =========  =============  ================  =====================  ============ 
 
 
Audited- 31 December 
2021 
At 18 January 2021                  -          -              -                 -                      -             - 
Loss for the year                   -          -              -                 -              (988,195)     (988,195) 
Exchange differences 
 on translation of 
 foreign operations                 -          -              -          (14,065)                      -      (14,065) 
Total comprehensive 
 profit/(loss) for the 
 period                             -          -              -          (14,065)              (988,195)   (1,002,260) 
                        -------------  ---------  -------------  ----------------  ---------------------  ------------ 
Transactions with 
Owners 
Issue of ordinary 
 shares                        27,597    859,539              -                 -                      -       887,136 
Issue of bonus shares          45,774   (45,774)              -                 -                      -             - 
Capital Reduction                   -  (180,000)              -                 -                180,000             - 
Merger of entity under 
 common control                     -          -              -           170,248                      -       170,248 
                        -------------  ---------  -------------  ----------------  ---------------------  ------------ 
Total Transactions 
 with owners                   73,371    633,765              -           170,248                180,000     1,057,384 
                        -------------  ---------  -------------  ----------------  ---------------------  ------------ 
At 31 December 2021 
 (audited)                     73,371    633,765              -           156,183              (808,195)        55,124 
                        =============  =========  =============  ================  =====================  ============ 
 
   1.             Reporting Entity 

Genflow Biosciences Plc (the "Company" or the "Group") is a company domiciled in the United Kingdom. The consolidated interim financial information as at and for the six months ended 30 June 2022 comprise the results of the Company and its subsidiaries (together referred to as the "Group").

The consolidated financial statements of the Group as at and for the year ended 31 December 2021 are available upon request from the Company's registered office at Suite 1, 15 Ingestre Place, London, England, W1F 0DU or at genflowbio.com .

   2.             BASIS OF PREPARATION 

The financial information set out in this report is based on the consolidated financial information of Genflow Biosciences Plc and its subsidiary companies. The financial information of the Group for the 6 months ended 30 June 2022 was approved and authorised for issue by the Board on 29 September 2022. The interim results have not been audited. This financial information has been prepared in accordance with the accounting policies that are expected to be applied in the Report and Accounts of Genflow Biosciences Plc for the year ended 31 December 2021 and are consistent with the recognition and measurement requirements of IFRS as adopted by the United Kingdom. The comparative information for the full year ended 31 December 2021 is not the Group's full annual accounts for that period but has been derived from the annual financial statements for that period.

The consolidated financial information incorporates the results of Genflow Biosciences Plc and its subsidiaries undertakings as at 30 June 2022. The corresponding amounts are for the year ended 31 December 2021 and for the 6 month period ended 30 June 2021.

The Group financial information is presented in Pound Sterling and values are rounded to the nearest pound.

The same accounting policies, presentation and methods of computation are followed in the interim consolidated financial information as were applied in the Group's latest annual audited financial statements except for those that relate to new standards and interpretations effective for the first time for periods beginning on (or after) 1 January 2022 and will be adopted in the 2022 annual financial statements.

A number of new standards, amendments and became effective on 1 January 2022 and have been adopted by the Group. None of these standards have materially affected the Group.

   3.             GOING CONCERN 

Although the Group's assets are not generating revenue streams, an operating loss has been reported and an operating loss is expected in the 12 months to 30 June 2023, the Directors believe that the Group will have sufficient funds to meet its immediate working capital requirements and undertake its targeted operating activities over the next 18 months from the date of approval of these financial statements. During the period, the Company received net proceeds of GBP3,499,516 from the issuance of 47,036,500 Ordinary Shares, and the Group has retained the majority of these funds with GBP2,945,624 in cash at the period end. During the period, the Group received notification that it had been awarded a non-dilutive research grant award of up to EUR3.375m from the regional government of Wallonia in southern Belgium. The funds are yet to be received, however management hope to use the funds to expedite certain phases of its planned research and development. Management has prepared forecast covering 18 month post-period end and believe that current cash reserves will adequately cover the working capital requirements of the Group in addition to meeting research and development commitments.

As such, the Directors have a reasonable expectation that the Group has and will have future access to adequate resources to continue in operational existence for the foreseeable future and, therefore, continue to adopt the going concern basis in preparing the Annual Report and financial statements.

   4.             EXPENSES BY NATURE 
 
                                           Unaudited       Unaudited        Audited 
                                            6 Months        6 Months     Year ended 
                                               ended           ended    31 December 
                                        30 June 2022    30 June 2021           2021 
------------------------------------  --------------  --------------  ------------- 
 
 Directors' fees                             172,851          18,534        166,441 
 Professional, legal and consulting 
  fees                                       267,535         135,431        386,325 
 PR and marketing                             89,935          18,960        138,933 
 Accounting related services                     591          27,103         95,530 
 Insurance                                    17,305               -          4,340 
 Office and administrative expenses            2,303           6,394          3,531 
 IT and software services                        396          16,479         27,199 
 Travel and entertainment                     15,062           2,048          6,668 
 Research and development costs               97,304          75,551         86,044 
 AIM costs                                    26,177          66,729         18,960 
 Other expenses                                6,943           5,062          4,125 
------------------------------------  --------------  --------------  ------------- 
 Total administrative expenses               696,402         372,291        938,096 
------------------------------------  --------------  --------------  ------------- 
 
   5.             PROFIT/(LOSS) PER SHARE 
 
                                                    Unaudited     Unaudited 
                                                     6 Months      6 Months        Audited 
                                                        ended         ended     Year ended 
                                                      30 June       30 June    31 December 
                                                         2022          2021           2021 
 
            Net loss for the year from 
             continued operations attributable 
             to equity shareholders                 (773,794)     (374,062)      (988,195) 
 
            Weighted average number 
             of shares for the period/year        289,858,193   216,113,467    166,669,960 
 
            Basic profit/(loss) per 
             share for continued operations 
             (expressed in pence)                     (0.267)        (0.17)        (0.593) 
                                                 ------------  ------------  ------------- 
 
   6.             Share capital 
 
 Company                               Number of   Ordinary       Share       Total 
                                          shares     shares     premium         GBP 
                                                        GBP         GBP 
--------------------------------  --------------  ---------  ----------  ---------- 
 Issued and fully paid 
--------------------------------  --------------  ---------  ----------  ------------ 
 Issued on incorporation                     100          1           -             1 
--------------------------------  --------------  ---------  ----------  ------------ 
 Issue of new shares - 25 March 
  2021                                 6,312,500        630     251,869       252,499 
--------------------------------  --------------  ---------  ----------  ------------ 
 Issue of new shares - 1 April 
  2021                               203,833,878     20,383           -        20,383 
--------------------------------  --------------  ---------  ----------  ------------ 
 Issue of new shares - 2 June 
  2021                                18,724,000      1,872     407,938       409,810 
--------------------------------  --------------  ---------  ----------  ------------ 
 At 30 June 2021                     228,870,478     22,886     659,807       682,693 
--------------------------------  --------------  ---------  ----------  ------------ 
 Issue of bonus shares on a 
  2:1 basis - 13 July 2021           457,740,956     45,774    (45,774)             - 
--------------------------------  --------------  ---------  ----------  ------------ 
 Consolidation of share capital                                       - 
  - 13 July 2021                   (457,740,956)          -                         - 
--------------------------------  --------------  ---------  ----------  ------------ 
 Capital reduction - 13 July 
  2021                                         -          -   (180,000)     (180,000) 
 Issue of Ordinary Shares - 
  9 November 2021                     15,699,640      4,711     199,732       204,443 
--------------------------------  --------------  ---------  ----------  ------------ 
 At 31 December 2021                 244,570,118     73,371     633,765       707,136 
--------------------------------  --------------  ---------  ----------  ------------ 
 Issue of Ordinary Shares - 
  17 January 2022                     47,936,500     14,381   3,820,539     3,834,920 
--------------------------------  --------------  ---------  ----------  ------------ 
 Deduction of cost of capital                  -          -   (263,404)     (263,404) 
 At 30 June 2022                     292,506,618     87,752   4,190,900   4,278,652 
--------------------------------  --------------  ---------  ----------  ---------- 
 

On 17 January 2022, the Company issued and allotted 47,036,500 new Ordinary Shares at a price of 8 pence per share for gross proceeds of GBP3,762,920. On the same day, the Company issued and allotted 900,000 new Ordinary Shares at nominal value in lieu of fees of GBP72,000.

   7.             COMMITMENTS 

The commitments stated in the Group's Annual Financial Statements for the year ended 31 December 2021 remain in place.

   8.             EVENTS AFTER THE REPORTING DATE 

On 15 July 2022 and 18 July 2022, Eric Leire, a director of the company, purchased 308,999 ordinary shares at a weighted average price per ordinary share of 3.03p.

On 18 July 2022, Yassine Bendiabdallah, Chairman of the Company, and Peter King-Lewis, a non-executive director of the Company, each purchased 108,000 and 82,000 ordinary shares respectfully, both at a weighted average price per ordinary share of 0.037.

On 18 August 2022, Eric Leire, a director of the company, purchased 106,000 ordinary shares at a weighted average price per ordinary share of 2.8p.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

For further information please contact:

 
 Genflow Biosciences Plc 
 Dr Eric Leire                         via Tancredi +44 203 434 2330 
  Chief Executive 
                                      ------------------------------ 
 Clear Capital Markets Ltd 
                                      ------------------------------ 
 Corporate Broker 
  Jonathan Critchley                   +44 203 869 6086 
  Keith Swann                           +44 203 897 0981 
                                      ------------------------------ 
 Tancredi Intelligent Communication 
  Media Relations 
                                      ------------------------------ 
 Salamander Davoudi                    +44 7957 549 906 
  Helen Humphrey                        +44 7449 226 720 
  Benedetta Negri da Oleggio            +44 7838 029 970 
                                        genflowbio@tancredigroup.com 
                                      ------------------------------ 
 

About Genflow

Genflow is a UK-based biotechnology company established in 2020. The Company is developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting aging in humans by using adeno-associated virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is found in centenarians into cells.

Its mission is to increase understanding of the factors that control and impact lifespan. Genflow researches, develops, and commercialises therapeutic solutions to lengthen health span, the amount of time we live in good health, creating biological interventions that enable longer and healthier lives. Genflow is dedicated to the development and commercialisation of novel therapeutics targeting aging in dogs and humans. By treating aging, Genflow can contribute to a decrease in healthcare costs and lessen the emotional and societal burden that comes with an aging population.

To learn more visit www.genflowbio.com

-Ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IR GSGDCGGXDGDG

(END) Dow Jones Newswires

September 30, 2022 02:02 ET (06:02 GMT)

1 Year Genflow Biosciences Chart

1 Year Genflow Biosciences Chart

1 Month Genflow Biosciences Chart

1 Month Genflow Biosciences Chart
Your Recent History
LSE
GENF
Genflow Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20230207 14:29:11